Sunday, June 21, 2026
Lilly is named in a deal with Abridge and Nvidia, but no peptide or drug program details are available from the source.
Eli Lilly and basketball star Shaquille O'Neal launched a marketing campaign called Watch This to talk about obstructive sleep apnea (a breathing problem during sleep). Zepbound (tirzepatide) is now approved as the first drug for this condition in adults who also have obesity.
Lilly is pushing Zepbound into a new patient group — people with sleep apnea and obesity. A celebrity campaign can drive awareness and new prescriptions.
Eli Lilly's pill version of orforglipron (Foundayo) beat Novo Nordisk's semaglutide pill at lowering blood sugar and weight loss in three large diabetes trials. Foundayo showed bigger drops in A1C levels and weight compared to the competing drug.
Lilly's orforglipron pill beat Novo's semaglutide pill on blood sugar and weight in three trials. That puts Lilly in a strong spot in the oral diabetes drug race.
Eli Lilly released new safety and side-effect data on retatrutide, its next-generation weight-loss drug. The data give doctors more details about how the drug works in patients.
New safety data on Lilly's retatrutide gives doctors a clearer picture of the drug before it reaches later-stage trials.
Eli Lilly's Foundayo (orforglipron), an oral weight-loss drug you can take with food or water, helped women lose significant weight in two trials. Women in perimenopause lost up to 30.4 pounds, and those past menopause lost up to 28.2 pounds.
Orforglipron showed weight loss in women at all menopause stages. This expands the pool of patients Lilly can target with its oral GLP-1 pill.
Eli Lilly shared safety and tolerability data on retatrutide, its next-generation weight-loss drug, at the American Diabetes Association's annual meeting. The data shows how well the drug works and what side effects patients experienced during testing.
Lilly's retatrutide safety data at a major medical meeting helps show if the drug is safe enough to move forward. Good results push it closer to market.
Eli Lilly's retatrutide, a triple-action weight-loss drug, helped people lose an average of 70 pounds over 80 weeks in a major trial. The drug also reduced joint pain and improved sleep problems in people with obesity and related conditions.
Retatrutide cut weight, joint pain, and sleep problems in one trial. That makes Lilly's drug look stronger than current options for people with obesity plus other conditions.
Eli Lilly will present new study results on Foundayo (an oral weight-loss and diabetes drug), Mounjaro, and retatrutide at a major diabetes conference. The Foundayo data showed it worked better than two competing pills for type 2 diabetes.
Lilly is showing new data on three drugs at once. Foundayo beating rival pills for type 2 diabetes could help doctors choose it over competitors.
Eli Lilly said CVS Caremark will start covering its weight-loss drugs Foundayo and Zepbound for millions of Americans starting in June and October. Eligible patients may pay only $25 per month for their medicine.
Millions of Americans may soon pay just $25/month for Lilly's weight-loss drugs. Broader coverage through CVS Caremark means more patients can afford Zepbound and Foundayo.
Eli Lilly's new weight-loss pill Foundayo helped older adults lose up to 13% of their body weight in a large trial. The drug is taken once daily without needing to avoid food or water first.
Foundayo showed up to 13% weight loss in adults 65+ with obesity. This age group is a large, underserved market for Lilly's oral pill.
Eli Lilly's retatrutide, a weight-loss drug that works three different ways in the body, helped people in a major trial lose about one-quarter of their body weight. This result may be stronger than what competitors like Novo Nordisk have shown with their own weight-loss drugs.
Retatrutide hit its Phase 3 goal with around 25% body weight loss. That may top Novo Nordisk's drugs and puts Lilly in a strong spot in the obesity market.
Eli Lilly said its new obesity drug worked almost as well as weight-loss surgery in a late-stage trial. The company tested the drug on people struggling with weight to see if it could help them lose pounds.
Lilly says a new obesity drug matched surgery results in a late trial. No trial details or drug name were confirmed in the source.
Eli Lilly's retatrutide, a new weight-loss drug that works three different ways, helped people lose an average of 70 pounds in a big Phase 3 trial. Nearly half of patients lost at least 30% of their body weight, which is as much as people usually lose from weight-loss surgery.
Retatrutide's Phase 3 results show weight loss close to surgery levels. This puts Lilly ahead in the obesity drug race and pressures rivals like Novo Nordisk.
Eli Lilly's retatrutide (a three-hormone weight-loss drug) helped patients lose as much weight as bariatric surgery in a trial. However, some patients quit the study because of side effects.
Lilly's retatrutide matched bariatric surgery weight loss in a trial. That is a big deal for people who can't or won't have surgery.
Eli Lilly's trial data suggests that people losing weight on high-dose shot versions of its drug could switch to lower doses or pills and still keep the weight off. The findings point to cheaper, easier ways to maintain weight loss once someone has hit their goal.
Lilly data suggest people could switch from costly high-dose shots to cheaper pills or lower doses and keep weight off. That widens how many patients can afford to stay on Lilly drugs long-term.
Eli Lilly released results from two late-stage trials showing that people who switched from higher-dose Wegovy or Zepbound to lower doses of Lilly's Foundayo pill or lower-dose Zepbound kept nearly all their weight loss over one year. The trials suggest the lower doses work well enough to maintain results when people switch from stronger versions.
Lilly's pill Foundayo may let patients step down from high-dose shots and keep their weight off. That could pull patients away from Novo's Wegovy.
No article body is available, so no specific facts can be confirmed about the Lilly vs. Novo competition story.
Eli Lilly's Foundayo (tirzepatide pill) hit 7,335 prescriptions in its fourth week on the market. The new drug is selling slower than Novo Nordisk's Wegovy, a competing weight-loss injection.
Lilly's new weight-loss pill is off to a slow start. Novo's Wegovy shot is still outselling it, so Novo keeps the lead in the obesity drug market.
Eli Lilly's obesity pill reached 7,000 prescriptions in its fourth week on the market. The number suggests a slow start compared to competing weight-loss drugs.
Lilly's new weight-loss pill is selling slower than hoped. That could give rivals like Novo more time to catch up in the pill race.
Lilly is spending GLP-1 drug profits on buyouts. Terns was bought by Merck, not a peptide play.
Eli Lilly's new obesity drug retatrutide is so effective that people are already making illegal copies of it. The drug hasn't even been fully approved yet, but compounding pharmacies are producing their own versions.
Lilly's next weight-loss drug retatrutide is already being copied before approval. That could pull sales from Lilly and spark a new FDA fight over copycat pharmacies.
Eli Lilly's tirzepatide (sold as Mounjaro for diabetes) brought in $5 billion more in sales than its cancer drug Keytruda in 2025. In early 2026, Mounjaro sales grew even larger and surpassed Keytruda's quarterly revenue.
Lilly's tirzepatide is now its biggest drug, beating the old top seller Keytruda. This shows how huge the weight-loss and diabetes market has become.
A market report says GLP-1 drug sales could hit $180 billion by 2035. That points to years of strong growth for Novo and Lilly.
Eli Lilly's Mounjaro (tirzepatide) is now the world's best-selling drug. The weight-loss and diabetes medicine has become more popular than all other drugs globally.
Mounjaro is now the top-selling drug in the world. That puts Lilly ahead of Novo's Ozempic in the race to dominate weight-loss and diabetes care.
Lilly is testing tirzepatide with a Regeneron drug to treat obesity. If it works, patients could get a stronger weight-loss option than Zepbound alone.
People are buying retatrutide, Eli Lilly's new weight-loss drug, on the black market because they can't get it through normal channels. The high demand shows how much people want the drug even before it's widely available.
People want Lilly's next weight-loss drug so badly they are buying it illegally before it is even approved. That signals huge demand once it launches.
Eli Lilly is spending $4.5 billion to build or expand a factory in Indiana. The investment likely supports production of tirzepatide (Mounjaro), Lilly's blockbuster weight-loss and diabetes drug.
More factory space means Lilly can make more Mounjaro and Zepbound. That helps ease the ongoing shortage of weight-loss shots.
Weight-loss pills could reach more people than shots. That would grow the market for Novo and Lilly instead of just splitting it.
Eli Lilly's tirzepatide (Mounjaro) is now the best-selling drug in the world. The drug treats both diabetes and weight loss, and its sales have grown faster than any other medicine.
Mounjaro is now the top-selling drug in the world. That shows how fast weight-loss and diabetes shots are taking over the drug market.
Novo's CEO says he is not worried about Lilly's new weight-loss pill. The two drugmakers are racing to win the pill market, not just shots.